Next Article in Journal
Translating Molecular Technologies into Routine Newborn Screening Practice
Previous Article in Journal / Special Issue
Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report
Open AccessArticle

Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II

1
Missouri State Public Health Laboratory, 101 N. Chestnut Street, PO Box 570, Jefferson City, MO 65102-0570, USA
2
Baebies, Inc., PO Box 14403, Durham, NC 27709, USA
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(4), 79; https://doi.org/10.3390/ijns6040079
Received: 16 September 2020 / Revised: 7 October 2020 / Accepted: 10 October 2020 / Published: 14 October 2020
(This article belongs to the Special Issue Neonatal Screening for Mucopolysaccharidoses)
Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, is a lysosomal storage disorder (LSD) caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). MPS II satisfies all criteria defined by the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) for inclusion in the Recommended Uniform Screening Panel (RUSP) for newborn screening, apart from the fact that only minimal prospective population screening data are available. This report details the analytical validation, clinical validation, and implementation of a fluorometric assay for measurement of IDS activity in newborn dried blood spot (DBS) specimens at the Missouri State Public Health Laboratory (MSPHL). The assay is performed in a microwell plate format requiring approximately 15 min of hands-on time per plate and an incubation time of two hours. The analytical validation of this assay included linearity, analytical sensitivity, precision, and carry-over testing. Clinical validation was completed using more than 5000 deidentified presumptive normal newborn DBS specimens as well as seven specimens from patients known to be affected with MPS II. Following validation, MSPHL began prospective screening using the IDS assay on 1 November 2018. In the first 18 months of screening (to 30 June 2020), 146,954 specimens were prospectively screened using the method. Two newborns were identified with severe Hunter syndrome and the assay had a presumptive positive rate of 0.022%. View Full-Text
Keywords: Hunter syndrome; mucopolysaccharidosis II; newborn screening; analytical validation; clinical validation Hunter syndrome; mucopolysaccharidosis II; newborn screening; analytical validation; clinical validation
Show Figures

Figure 1

MDPI and ACS Style

Bilyeu, H.; Washburn, J.; Vermette, L.; Klug, T. Validation and Implementation of a Highly Sensitive and Efficient Newborn Screening Assay for Mucopolysaccharidosis Type II. Int. J. Neonatal Screen. 2020, 6, 79.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop